NOVAVAX INC

NVAXSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1000694

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$983.7M	$2.0B	—	—	—
Cost of Revenue	$343.8M	$902.6M	$0.00	$0.00	—
Research and Development Expense	$737.5M	$1.2B	$2.5B	$747.0M	$113.8M
Selling, General and Administrative Expense	$468.9M	$488.7M	—	—	—
Operating Income (Loss)	-$566.5M	-$644.7M	-$1.7B	-$416.7M	-$120.6M
Interest Expense	—	—	$21.1M	$15.1M	$13.6M
Other Nonoperating Income (Expense)	$37.9M	$11.0M	-$6.8M	$13.6M	-$13.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$1.6B	$1.8B	$2.3B	$2.6B	$1.6B
Assets, Current	$1.1B	$1.1B	$1.7B	$2.2B	$1.2B
Cash and Cash Equivalents, at Carrying Value	$568.5M	$1.3B	$1.5B	$553.4M	$553.4M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	—	—	—
Inventory, Net	$8.7M	$41.7M	$36.7M	$8.9M	—
Liabilities	$2.2B	$2.5B	$2.9B	$2.9B	$955.3M
Liabilities, Current	$1.2B	$1.6B	$2.5B	$2.4B	$579.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$714.0M	-$415.9M	$322.9M	-$42.5M	-$136.6M
Net Cash Provided by (Used in) Investing Activities	-$58.8M	-$93.0M	$100.2M	-$377.8M	$38.5M
Net Cash Provided by (Used in) Financing Activities	$4.5M	$325.0M	$461.7M	$984.8M	$98.4M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)